The UK and US have finalized a landmark bilateral deal that will maintain no import taxes on UK medicine exports being sold in the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to boost spending on medicines through the NHS. This pledge guarantees that duties on these key products will remain at zero for a duration of three years.
This agreement is in response to recent statements to hike tariffs on branded pharmaceutical products, with figures discussed up to one hundred percent.
"This arrangement with the United Kingdom bolsters the global environment for new treatments and introduces long-overdue balance to American-British drug exports," a release said.
Economic Importance
Medicines constitute one of the Britain's biggest exports to the United States, which is clearly the largest buyer for major UK drugmakers.
Export figures reveal that in the 12 months leading up to September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value made up 17.4% of all goods exports in that timeframe.
"This deal protects work, increases funding and sets the stage for the UK to become a global hub for biotech and pharma," a government official commented.
Specific UK Commitments
The pact involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to raise total public funding on medicines from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds topped twenty percent.
Broader Context
This agreement follows a long-running tension between the drug companies and the ministers over drug pricing and regulatory access.
This friction were exacerbated by claims that US customers were paying a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or scrapped, while substantial investments have been directed toward American operations.
One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
